Ananda Pharma Plc Stock Price

Ananda Pharma Plc, along with its subsidiaries, operate as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials for refractory epilepsies. In addition, it engages in crop production; growing of vegetables, melons, and roots and tubers; the wholesale of pharmaceutical goods; the development and distribution of health products; and the manufacture of other organic basic and essential oils. The company was formerly known as Ananda Developments Plc and changed its name to Ananda Pharma Plc in December 2024. Ananda Pharma Plc was incorporated in 2018 and is based in London, the United Kingdom.